Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
Activation of the complement system through the alternative pathway is necessary for the development of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in animal models C5a has ...
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune response FDA granted EUA based on Phase III ...
InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody Jena, Germany, January 28th 2016 - InflaRx, a ...
Significantly elevated baseline C5a levels occur in hidradenitis suppurativa (HS) patients Vilobelimab dose-dependently suppresses C5a levels over time accompanied by the previously reported reduction ...
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced ...
Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...
It is known that dendritic cells and innate lymphoid cells type 2 (ILC2) play key roles in allergen sensitization, and humoral factors such as complement C3a and complement C5a are highly involved in ...
InflaRx will also conduct one-on-one investor meetings on February 25 th. A link to view the virtual presentation and its ...
JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results